AbbVie Inc. has released its preliminary earnings guidance for the first quarter of 2026, indicating a significant impact from acquired in-process research and development (IPR&D) and milestones expenses totaling $744 million. This expense is expected to adversely affect both GAAP and adjusted non-GAAP diluted earnings per share by $0.41. The company has stated that the results for the quarter ending March 31, 2026, are still subject to finalization and may differ from these preliminary estimates. AbbVie has previously excluded the impact of such expenses from its adjusted diluted earnings per share guidance for 2026, which is now projected to range between $13.96 and $14.16 for the full year. For the first quarter, the adjusted diluted earnings per share guidance is set between $2.56 and $2.60, inclusive of the IPR&D expenses. The company has cautioned that while these expenses may arise from collaborations and licensing agreements, they cannot be reliably forecasted due to the uncertainty surrounding the timing and occurrence of such transactions. This announcement comes as AbbVie continues to navigate the complexities of its financial landscape, with the potential for further adjustments as the company finalizes its financial statements.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.